Aadi Bioscience (AADI) announced that Kaken Pharmaceutical, an R&D driven pharmaceutical company in Japan, has entered into a stock purchase agreement under which Kaken will acquire Aadi Subsidiary and all of its assets, including Fyarro and associated infrastructure, including the majority of Aadi employees who support the Fyarro business. Fyarro is approved by the FDA for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, with cumulative revenue of $25.2M reported over the prior four quarters ended September 30, 2024. The transaction is expected to close in 1H25, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, Kaken will also acquire the rights to the Aadi name and trademark. The net proceeds from the PIPE financing and the sale of Kaken, together with the company’s existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AADI:
- Aadi Bioscience Faces Potential Financial Strain from Securities Class Action Risks
- Aadi Bioscience Reports Q3 2024 Earnings and Growth
- Aadi Bioscience reports Q3 EPS (46c), consensus (46c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
